SG11201804412SA - Dimeric contrast agents - Google Patents

Dimeric contrast agents

Info

Publication number
SG11201804412SA
SG11201804412SA SG11201804412SA SG11201804412SA SG11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA
Authority
SG
Singapore
Prior art keywords
international
colleretto
giacosa
ribes
crb
Prior art date
Application number
SG11201804412SA
Other languages
English (en)
Inventor
Valeria Boi
Roberta Napolitano
Luciano Lattuada
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of SG11201804412SA publication Critical patent/SG11201804412SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/122Macromolecular compounds dimers of complexes or complex-forming compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201804412SA 2015-12-10 2016-12-12 Dimeric contrast agents SG11201804412SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15199220 2015-12-10
PCT/EP2016/080621 WO2017098044A1 (en) 2015-12-10 2016-12-12 Dimeric contrast agents

Publications (1)

Publication Number Publication Date
SG11201804412SA true SG11201804412SA (en) 2018-06-28

Family

ID=55027251

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804412SA SG11201804412SA (en) 2015-12-10 2016-12-12 Dimeric contrast agents

Country Status (22)

Country Link
US (3) US10407412B2 (ko)
EP (2) EP3753929B1 (ko)
JP (1) JP6896733B2 (ko)
KR (1) KR102703336B1 (ko)
CN (1) CN108368067B (ko)
AU (1) AU2016368545C1 (ko)
BR (1) BR112018010815B1 (ko)
CA (1) CA3002897C (ko)
DK (2) DK3753929T3 (ko)
ES (2) ES2843998T3 (ko)
FI (1) FI3753929T3 (ko)
HR (2) HRP20221451T1 (ko)
HU (2) HUE060536T2 (ko)
IL (1) IL259836B (ko)
LT (1) LT3386954T (ko)
MX (1) MX2018007043A (ko)
PL (2) PL3753929T3 (ko)
PT (1) PT3386954T (ko)
RU (1) RU2739834C2 (ko)
SG (1) SG11201804412SA (ko)
SI (2) SI3753929T1 (ko)
WO (1) WO2017098044A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
SI3753929T1 (sl) * 2015-12-10 2023-01-31 Bracco Imaging Spa Dimerna kontrastna sredstva
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
WO2018108780A1 (en) * 2016-12-12 2018-06-21 Bracco Imaging Spa Dimeric contrast agents
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
AU2020399182A1 (en) 2019-12-13 2022-06-09 Bracco Imaging Spa Manufacturing of protected DO3A
US20230303592A1 (en) 2020-07-27 2023-09-28 Bracco Imaging S.P.A. Manufacturing of dimeric contrast agents
KR20230116805A (ko) * 2020-12-04 2023-08-04 브라코 이미징 에스.피.에이. 가도테리돌 제조를 위한 제조 방법
AU2022317221A1 (en) * 2021-07-27 2023-11-16 Bracco Imaging Spa Manufacturing of dimeric contrast agents
KR20240038926A (ko) 2021-07-27 2024-03-26 브라코 이미징 에스.피.에이. 가돌리늄 착물 용액의 제조 과정
WO2023110863A1 (en) 2021-12-14 2023-06-22 Bracco Imaging Spa Process for manufacturing a mixture comprising a dimeric macrocycle intermediate of a gadolinium complex
EP4448499A1 (en) 2021-12-14 2024-10-23 Bracco Imaging SPA Manufacturing of dimeric contrast agent
WO2024074648A1 (en) 2022-10-07 2024-04-11 Bracco Imaging Spa Precipitation and isolation of gadolinium complex

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9318550D0 (en) * 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
IT1292128B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
AU752812B2 (en) * 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
DE19849465A1 (de) * 1998-10-21 2000-04-27 Schering Ag Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
DE10117242C1 (de) * 2001-04-06 2002-05-16 Schering Ag Unsymmetrische dimere Metallkomplexe, Liganden für diese Metallkomplexe, Verfahren zu deren Herstellung, Arzneimittel bzw. Diagnosemittel, die die Metallkomplexe enthalten, insbesondere Kontrastmittel
US6852854B1 (en) * 2002-10-01 2005-02-08 Psiloquest Inc. Preformed carboxylated active ester for labeling biomolecules
US7208140B2 (en) 2003-02-19 2007-04-24 Schering Aktiengesellschaft Trimeric macrocyclic substituted benzene derivatives
CN1993357B (zh) * 2004-07-02 2011-10-19 伯拉考成像股份公司 用于磁共振成像(mri)的含有具有多羟基化取代基的螯合部分的高弛豫造影剂
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
RU2425831C2 (ru) * 2005-12-02 2011-08-10 Джи-И Хелткер АС Мультимерные контрастные агенты для магнитного резонанса
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
EP2457594A1 (en) * 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9315524B2 (en) 2012-05-07 2016-04-19 Kumar Ranjan Bhushan Magnetic resonance imaging agents for calcification
CN102727911B (zh) 2012-07-09 2013-07-24 中国科学院长春应用化学研究所 双氨基聚乙二醇修饰的顺磁性金属配合物磁共振成像造影剂
US9155804B2 (en) 2012-09-26 2015-10-13 General Electric Company Contrast enhancement agents and method of use thereof
US10786497B2 (en) 2013-08-16 2020-09-29 Equip, Llc Discrete PEG constructs
SI3753929T1 (sl) * 2015-12-10 2023-01-31 Bracco Imaging Spa Dimerna kontrastna sredstva

Also Published As

Publication number Publication date
CA3002897C (en) 2022-03-29
IL259836B (en) 2021-07-29
US20190345142A1 (en) 2019-11-14
HRP20221451T1 (hr) 2023-02-17
KR102703336B1 (ko) 2024-09-06
US10407412B2 (en) 2019-09-10
ES2843998T3 (es) 2021-07-21
JP2019501153A (ja) 2019-01-17
EP3386954A1 (en) 2018-10-17
IL259836A (en) 2018-07-31
EP3753929A1 (en) 2020-12-23
WO2017098044A1 (en) 2017-06-15
HUE052680T2 (hu) 2021-05-28
US20210024500A1 (en) 2021-01-28
US20180362511A1 (en) 2018-12-20
MX2018007043A (es) 2018-08-15
EP3753929B1 (en) 2022-10-26
RU2018123572A (ru) 2020-01-13
RU2018123572A3 (ko) 2020-02-10
PL3386954T3 (pl) 2021-06-14
DK3386954T3 (da) 2021-02-15
US11401262B2 (en) 2022-08-02
CA3002897A1 (en) 2017-06-15
AU2016368545B2 (en) 2020-09-03
KR20180090823A (ko) 2018-08-13
EP3386954B1 (en) 2020-12-02
SI3386954T1 (sl) 2021-02-26
CN108368067B (zh) 2022-04-29
SI3753929T1 (sl) 2023-01-31
FI3753929T3 (fi) 2023-01-31
DK3753929T3 (da) 2023-01-23
CN108368067A (zh) 2018-08-03
PL3753929T3 (pl) 2023-03-13
US10882849B2 (en) 2021-01-05
HUE060536T2 (hu) 2023-03-28
RU2739834C2 (ru) 2020-12-28
ES2932302T3 (es) 2023-01-17
PT3386954T (pt) 2021-01-07
NZ741900A (en) 2021-10-29
BR112018010815A2 (pt) 2018-11-27
LT3386954T (lt) 2021-04-12
AU2016368545C1 (en) 2021-01-07
HRP20210061T1 (hr) 2021-03-05
AU2016368545A1 (en) 2018-05-10
BR112018010815B1 (pt) 2022-05-17
US20200331893A9 (en) 2020-10-22
JP6896733B2 (ja) 2021-06-30

Similar Documents

Publication Publication Date Title
SG11201804412SA (en) Dimeric contrast agents
SG11201804415QA (en) Contrast agents
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407898WA (en) Electrode testing apparatus
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201909011PA (en) Niraparib compositions
SG11201408261UA (en) Syringe
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201909003YA (en) Integrated vascular access device and anchor pad
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201807250PA (en) Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
SG11201408808WA (en) Method and system for treatment of biological tissue
SG11201808686VA (en) Synthesis of indazoles
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors